首页 > 最新文献

Indian journal of cancer最新文献

英文 中文
Lineage switch of acute myeloid leukemia to B-lymphoblastic leukemia in an adult at relapse with review of literature. 成人复发急性髓性白血病向b淋巴细胞白血病的谱系转换及文献回顾。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_69_22
Manasi C Mundada, Bharath Potturu, Faiq Ahmed, Boyella Pavan Kumar

Abstract: "Lineage switch" is a term used to describe the phenomenon of change of lineage of acute leukemia to a different lineage. It is typically seen during therapy or at the time of relapse. More commonly, it is described in the pediatric population with an incidence of 6-9%. Lineage switches, though uncommon, can occur from acute myeloid leukemia (AML) to acute lymphoblastic leukemia (ALL (B/T)) and vice versa. The present scenario of AML to B-ALL switch is rare in an adult, with only a handful of cases described in literature. We report herein a case diagnosed as AML at 56 years of age, with NPM mutation who relapsed after 18 months post initial diagnosis. The clinicopathological features, flowcytometry, and molecular characteristics are discussed.

摘要:“谱系切换”是用来描述急性白血病谱系向不同谱系改变的现象。它通常在治疗期间或复发时出现。更常见的是,它在儿科人群中发病率为6-9%。谱系切换,虽然不常见,但可以发生从急性髓性白血病(AML)到急性淋巴细胞白血病(ALL (B/T)),反之亦然。目前AML到B-ALL转换的情况在成人中很少见,文献中只描述了少数病例。我们在此报告一例56岁诊断为AML的病例,NPM突变在初次诊断后18个月复发。临床病理特征,流式细胞术和分子特征进行了讨论。
{"title":"Lineage switch of acute myeloid leukemia to B-lymphoblastic leukemia in an adult at relapse with review of literature.","authors":"Manasi C Mundada, Bharath Potturu, Faiq Ahmed, Boyella Pavan Kumar","doi":"10.4103/ijc.ijc_69_22","DOIUrl":"10.4103/ijc.ijc_69_22","url":null,"abstract":"<p><strong>Abstract: </strong>\"Lineage switch\" is a term used to describe the phenomenon of change of lineage of acute leukemia to a different lineage. It is typically seen during therapy or at the time of relapse. More commonly, it is described in the pediatric population with an incidence of 6-9%. Lineage switches, though uncommon, can occur from acute myeloid leukemia (AML) to acute lymphoblastic leukemia (ALL (B/T)) and vice versa. The present scenario of AML to B-ALL switch is rare in an adult, with only a handful of cases described in literature. We report herein a case diagnosed as AML at 56 years of age, with NPM mutation who relapsed after 18 months post initial diagnosis. The clinicopathological features, flowcytometry, and molecular characteristics are discussed.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"445-448"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tobacco use among Taxi Drivers in Mumbai, India: Prevalence and predictors. 印度孟买出租车司机的烟草使用:流行程度和预测因素。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_1119_22
Subhadra D Gupta, Gauravi A Mishra, Sharmila A Pimple, Vasundhara Y Kulkarni, Anil S Patil, Heena Kauser A Shaikh, Parishi V Majmudar

Background: Addiction to various forms of tobacco, odd work hours with idle breaks in between, and the lack of targeted tobacco cessation services make taxi drivers vulnerable to a range of tobacco-related diseases and cancers.

Methodology: A total of 400 taxi drivers from Mumbai were enrolled in the study and interviewed using a well-structured questionnaire to collect information about their attitudes, practices regarding tobacco usage, and efforts to quit, after obtaining informed consent. Participants were further provided with health education on the hazards of tobacco use and the importance of smoke-free taxis by trained medical social workers.

Results: The prevalence of current tobacco use was 63.8% (95% CI: 58.8% - 68.5%). Smokeless tobacco was predominant (85.1%), with Khaini (55.7%) being the most commonly used form. The mean age of participants was 39.15 years, and the average age of initiation was 25 years. Curiosity was the primary reason for initiation (45.9%). Graduates and non alcoholic drivers were less likely to use tobacco (OR =0.13 and 0.29, respectively), and this difference was statistically significant. Among the users, 94.5% expressed a desire to quit, 66.3% had attempted to quit, and 69.8% felt they needed assistance to quit.

Conclusion: The study identifies the patterns and predictors of tobacco use among taxi drivers, as well as their need for assistance to quit. These findings will help guide the development of prevention and cessation strategies, ultimately aiming to reduce the risks faced by this population.

背景:对各种形式的烟草上瘾,工作时间不规律,中间有空闲休息,以及缺乏有针对性的戒烟服务,使出租车司机容易罹患一系列与烟草有关的疾病和癌症。方法:来自孟买的总共400名出租车司机参加了这项研究,并使用结构良好的问卷进行了采访,以收集有关他们对烟草使用的态度、做法以及在获得知情同意后戒烟的努力的信息。培训有素的医务社会工作者还向与会者提供了关于吸烟危害和无烟出租车重要性的健康教育。结果:当前烟草使用率为63.8% (95% CI: 58.8% - 68.5%)。无烟烟草占多数(85.1%),Khaini(55.7%)是最常用的烟草形式。参与者的平均年龄为39.15岁,平均开始年龄为25岁。好奇心是开始的主要原因(45.9%)。大学毕业生和非酒精驾驶员吸烟的可能性较低(OR分别为0.13和0.29),这一差异具有统计学意义。94.5%的人表示有戒烟的愿望,66.3%的人曾尝试戒烟,69.8%的人认为戒烟需要帮助。结论:该研究确定了出租车司机吸烟的模式和预测因素,以及他们对戒烟帮助的需求。这些发现将有助于指导预防和戒烟策略的制定,最终旨在减少这一人群面临的风险。
{"title":"Tobacco use among Taxi Drivers in Mumbai, India: Prevalence and predictors.","authors":"Subhadra D Gupta, Gauravi A Mishra, Sharmila A Pimple, Vasundhara Y Kulkarni, Anil S Patil, Heena Kauser A Shaikh, Parishi V Majmudar","doi":"10.4103/ijc.ijc_1119_22","DOIUrl":"10.4103/ijc.ijc_1119_22","url":null,"abstract":"<p><strong>Background: </strong>Addiction to various forms of tobacco, odd work hours with idle breaks in between, and the lack of targeted tobacco cessation services make taxi drivers vulnerable to a range of tobacco-related diseases and cancers.</p><p><strong>Methodology: </strong>A total of 400 taxi drivers from Mumbai were enrolled in the study and interviewed using a well-structured questionnaire to collect information about their attitudes, practices regarding tobacco usage, and efforts to quit, after obtaining informed consent. Participants were further provided with health education on the hazards of tobacco use and the importance of smoke-free taxis by trained medical social workers.</p><p><strong>Results: </strong>The prevalence of current tobacco use was 63.8% (95% CI: 58.8% - 68.5%). Smokeless tobacco was predominant (85.1%), with Khaini (55.7%) being the most commonly used form. The mean age of participants was 39.15 years, and the average age of initiation was 25 years. Curiosity was the primary reason for initiation (45.9%). Graduates and non alcoholic drivers were less likely to use tobacco (OR =0.13 and 0.29, respectively), and this difference was statistically significant. Among the users, 94.5% expressed a desire to quit, 66.3% had attempted to quit, and 69.8% felt they needed assistance to quit.</p><p><strong>Conclusion: </strong>The study identifies the patterns and predictors of tobacco use among taxi drivers, as well as their need for assistance to quit. These findings will help guide the development of prevention and cessation strategies, ultimately aiming to reduce the risks faced by this population.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"388-394"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Septal chondrosarcoma- An unusual cause of nasal obstruction. 鼻中隔软骨肉瘤-一种罕见的鼻塞病因。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_1196_21
Daisy A David, Reshma Kurian, Regi Kurien, Lalee Varghese

Abstract: Chondrosarcomas are slow-growing malignant tumors of cartilaginous origin. The tumor can be locally aggressive with a risk of recurrence. Less than 10% of these tumors occur in the head and neck region, with most involving the maxilla, skull base, or larynx. Chondrosarcoma arising from the nasal septum is extremely rare. We report a case of a 64-year-old woman who presented with nasal obstruction and was subsequently diagnosed with nasal septal chondrosarcoma. She was treated with wide endoscopic surgical excision and regular follow-up, resulting in a good outcome.

摘要:软骨肉瘤是一种起源于软骨的生长缓慢的恶性肿瘤。肿瘤可局部侵袭,有复发的危险。不到10%的肿瘤发生在头颈部,大多数累及上颌骨、颅底或喉部。起源于鼻中隔的软骨肉瘤极为罕见。我们报告一例64岁的妇女谁提出鼻塞和随后被诊断为鼻中隔软骨肉瘤。她接受了广泛的内镜手术切除和定期随访,结果良好。
{"title":"Septal chondrosarcoma- An unusual cause of nasal obstruction.","authors":"Daisy A David, Reshma Kurian, Regi Kurien, Lalee Varghese","doi":"10.4103/ijc.ijc_1196_21","DOIUrl":"https://doi.org/10.4103/ijc.ijc_1196_21","url":null,"abstract":"<p><strong>Abstract: </strong>Chondrosarcomas are slow-growing malignant tumors of cartilaginous origin. The tumor can be locally aggressive with a risk of recurrence. Less than 10% of these tumors occur in the head and neck region, with most involving the maxilla, skull base, or larynx. Chondrosarcoma arising from the nasal septum is extremely rare. We report a case of a 64-year-old woman who presented with nasal obstruction and was subsequently diagnosed with nasal septal chondrosarcoma. She was treated with wide endoscopic surgical excision and regular follow-up, resulting in a good outcome.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"436-438"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing a comprehensive ICF core set to document health and functioning in children with Cancer in India: A preliminary study. 制定一套全面的国际癌症基金会核心文件,以记录印度癌症儿童的健康和功能:初步研究。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_103_24
Regi Merlinann, Selvaraj Samuelkamaleshkumar, Joel Ronaldthomvicmaradona, Agnes Anna Mathew, Rikki Rorima John, Gowri Mahasampath, Leni Grace Mathew

Background: This study aimed to develop a comprehensive ICF Core Set for children with cancer to facilitate the documentation of their health and functioning. Two preparatory phase studies were conducted to gather perspectives from caregivers and healthcare professionals.

Methods: Semi-structured interviews with caregivers and a cross-sectional survey with healthcare professionals were conducted to understand the challenges children face due to cancer and its treatment, as well as environmental factors impacting their functioning. Interviews were audio-recorded, transcribed verbatim, and analyzed qualitatively. The themes derived from the analysis were coded and linked to the ICF framework using Cieza linking rules.

Results: A comprehensive ICF Core Set comprising 156 categories was formulated by combining responses from 21 healthcare professionals and 18 caregivers. Categories were distributed across the body structure, body functions, activities/participation, and environmental factors domains. Specifically, 40 categories related to body structure, 65 to body functions, 23 to activities/participation, and 27 to environmental factors.

Conclusion: The use of the ICF to develop the Core Set is significant as it provides a multidimensional perspective on the health and functioning of children with cancer. Incorporating intrinsic and extrinsic factors, the Core Set can assist multidisciplinary treatment teams in delivering individualized and holistic care to pediatric patients. Additionally, it can serve as a foundation for standardizing assessment tools and planning preventative and intervention strategies for this population.

背景:本研究旨在为患有癌症的儿童开发一套全面的ICF核心集,以方便记录他们的健康和功能。进行了两项准备阶段的研究,以收集护理人员和医疗保健专业人员的观点。方法:对护理人员进行半结构化访谈,并对医疗保健专业人员进行横断面调查,以了解儿童因癌症及其治疗而面临的挑战,以及影响其功能的环境因素。访谈录音,逐字记录,并进行定性分析。通过对分析得出的主题进行编码,并使用Cieza链接规则将其链接到ICF框架。结果:综合21名医疗保健专业人员和18名护理人员的反馈,制定了包含156个类别的综合ICF核心集。类别分布在身体结构、身体功能、活动/参与和环境因素领域。具体来说,与身体结构有关的类别有40个,与身体功能有关的类别有65个,与活动/参与有关的类别有23个,与环境因素有关的类别有27个。结论:利用ICF制定核心集具有重要意义,因为它提供了一个关于癌症儿童健康和功能的多维视角。结合内在和外在因素,Core Set可以帮助多学科治疗团队为儿科患者提供个性化和整体的护理。此外,它可以作为标准化评估工具和规划预防和干预策略的基础。
{"title":"Developing a comprehensive ICF core set to document health and functioning in children with Cancer in India: A preliminary study.","authors":"Regi Merlinann, Selvaraj Samuelkamaleshkumar, Joel Ronaldthomvicmaradona, Agnes Anna Mathew, Rikki Rorima John, Gowri Mahasampath, Leni Grace Mathew","doi":"10.4103/ijc.ijc_103_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_103_24","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop a comprehensive ICF Core Set for children with cancer to facilitate the documentation of their health and functioning. Two preparatory phase studies were conducted to gather perspectives from caregivers and healthcare professionals.</p><p><strong>Methods: </strong>Semi-structured interviews with caregivers and a cross-sectional survey with healthcare professionals were conducted to understand the challenges children face due to cancer and its treatment, as well as environmental factors impacting their functioning. Interviews were audio-recorded, transcribed verbatim, and analyzed qualitatively. The themes derived from the analysis were coded and linked to the ICF framework using Cieza linking rules.</p><p><strong>Results: </strong>A comprehensive ICF Core Set comprising 156 categories was formulated by combining responses from 21 healthcare professionals and 18 caregivers. Categories were distributed across the body structure, body functions, activities/participation, and environmental factors domains. Specifically, 40 categories related to body structure, 65 to body functions, 23 to activities/participation, and 27 to environmental factors.</p><p><strong>Conclusion: </strong>The use of the ICF to develop the Core Set is significant as it provides a multidimensional perspective on the health and functioning of children with cancer. Incorporating intrinsic and extrinsic factors, the Core Set can assist multidisciplinary treatment teams in delivering individualized and holistic care to pediatric patients. Additionally, it can serve as a foundation for standardizing assessment tools and planning preventative and intervention strategies for this population.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"372-387"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olaparib and temozolomide combination in relapsed metastatic Ewing sarcoma brings a new ray of hope. 奥拉帕尼联合替莫唑胺治疗复发性转移性尤文氏肉瘤带来了新的希望。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_846_22
Deepak Gupta, Pawan Agarwal, Ajay Singh Chaudhary, Anushka Gupta

Abstract: Ewing sarcoma is a highly malignant neoplasm of bone or soft tissues that is predominantly seen in adolescents and young adults. Patients with recurrent and metastasis have poor survival despite aggressive treatment. In Ewing sarcoma, EWS-FLI-1 translocation has been identified as a biomarker for Poly-ADP ribose Polymerase inhibitor (PARPi) sensitivity and olaparib has been shown to enhance the antitumor activity of chemotherapy agents like temozolomide, irinotecan, and trabectedin. We tried the combination of olaparib and temozolomide in an adult patient of Ewing sarcoma who had metastatic disease, and after 4 months of treatment, he showed excellent response to treatment.

摘要:尤文氏肉瘤是一种高度恶性的骨或软组织肿瘤,主要见于青少年和青壮年。患者复发和转移,尽管积极的治疗生存率差。在尤文氏肉瘤中,EWS-FLI-1易位已被确定为Poly-ADP核糖聚合酶抑制剂(PARPi)敏感性的生物标志物,奥拉帕尼已被证明可以增强替莫唑胺、伊立替康和trabectedin等化疗药物的抗肿瘤活性。我们尝试了奥拉帕尼和替莫唑胺联合治疗一名患有转移性尤文氏肉瘤的成人患者,经过4个月的治疗,他对治疗表现出良好的反应。
{"title":"Olaparib and temozolomide combination in relapsed metastatic Ewing sarcoma brings a new ray of hope.","authors":"Deepak Gupta, Pawan Agarwal, Ajay Singh Chaudhary, Anushka Gupta","doi":"10.4103/ijc.ijc_846_22","DOIUrl":"10.4103/ijc.ijc_846_22","url":null,"abstract":"<p><strong>Abstract: </strong>Ewing sarcoma is a highly malignant neoplasm of bone or soft tissues that is predominantly seen in adolescents and young adults. Patients with recurrent and metastasis have poor survival despite aggressive treatment. In Ewing sarcoma, EWS-FLI-1 translocation has been identified as a biomarker for Poly-ADP ribose Polymerase inhibitor (PARPi) sensitivity and olaparib has been shown to enhance the antitumor activity of chemotherapy agents like temozolomide, irinotecan, and trabectedin. We tried the combination of olaparib and temozolomide in an adult patient of Ewing sarcoma who had metastatic disease, and after 4 months of treatment, he showed excellent response to treatment.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"451-453"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodal histiocytic sarcoma mimicking metastatic carcinoma, a challenging diagnosis - Case report of an extremely rare hematolymphoid neoplasm with recent updates. 模拟转移癌的结节组织细胞肉瘤,一个具有挑战性的诊断-一个极其罕见的血淋巴肿瘤病例报告,最近更新。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_1288_21
Gittwa V Kottangal, Shalini Kuruvilla, Kavitha K Parameswaran, Lilly Madhavan, Shehla B Kollathodi

Abstract: Histiocytic sarcoma (HS), a rare malignant neoplasm of hematolymphoid origin, belongs to the World Health Organization (WHO) classification of histiocytic and dendritic cell neoplasms. This rare aggressive malignancy occurs predominantly in adults and accounts for less than 1% of all hematolymphoid neoplasms. It arises from the monocytic/macrophage lineage and shares the histomorphologic and immunohistochemical features of mature tissue histiocytes. Its predominant presentation is extranodal, involving the intestinal tract, skin, and soft tissue, and it rarely presents with lymphadenopathy. The diagnosis of HS is entirely based on identifying the histiocytic lineage and the exclusion of other poorly differentiated malignancies with large pleomorphic cells like high-grade lymphomas, carcinoma, melanoma, germ cell tumors, and sarcomas. Herein, we report a case of a 61-year-old female patient who noticed a left supraclavicular swelling of 3 weeks duration, and the biopsy revealed a nodal HS. The clinicopathologic, histomorphologic, immunohistochemical, and molecular features of the disease will be further discussed.

摘要:组织细胞肉瘤(HS)是一种罕见的源自淋巴细胞的恶性肿瘤,属于世界卫生组织(WHO)的组织细胞肿瘤和树突状细胞肿瘤分类。这种罕见的侵袭性恶性肿瘤主要发生在成人中,占所有血淋巴肿瘤的不到1%。它起源于单核/巨噬细胞谱系,具有成熟组织组织细胞的组织形态学和免疫组织化学特征。其主要表现为结外,累及肠道、皮肤和软组织,很少表现为淋巴结病。HS的诊断完全基于组织细胞谱系的识别,并排除其他具有大多形性细胞的低分化恶性肿瘤,如高级别淋巴瘤、癌、黑色素瘤、生殖细胞瘤和肉瘤。在此,我们报告一例61岁的女性患者,她注意到左侧锁骨上肿胀持续3周,活检显示结节性HS。我们将进一步讨论本病的临床病理、组织形态学、免疫组织化学和分子特征。
{"title":"Nodal histiocytic sarcoma mimicking metastatic carcinoma, a challenging diagnosis - Case report of an extremely rare hematolymphoid neoplasm with recent updates.","authors":"Gittwa V Kottangal, Shalini Kuruvilla, Kavitha K Parameswaran, Lilly Madhavan, Shehla B Kollathodi","doi":"10.4103/ijc.ijc_1288_21","DOIUrl":"https://doi.org/10.4103/ijc.ijc_1288_21","url":null,"abstract":"<p><strong>Abstract: </strong>Histiocytic sarcoma (HS), a rare malignant neoplasm of hematolymphoid origin, belongs to the World Health Organization (WHO) classification of histiocytic and dendritic cell neoplasms. This rare aggressive malignancy occurs predominantly in adults and accounts for less than 1% of all hematolymphoid neoplasms. It arises from the monocytic/macrophage lineage and shares the histomorphologic and immunohistochemical features of mature tissue histiocytes. Its predominant presentation is extranodal, involving the intestinal tract, skin, and soft tissue, and it rarely presents with lymphadenopathy. The diagnosis of HS is entirely based on identifying the histiocytic lineage and the exclusion of other poorly differentiated malignancies with large pleomorphic cells like high-grade lymphomas, carcinoma, melanoma, germ cell tumors, and sarcomas. Herein, we report a case of a 61-year-old female patient who noticed a left supraclavicular swelling of 3 weeks duration, and the biopsy revealed a nodal HS. The clinicopathologic, histomorphologic, immunohistochemical, and molecular features of the disease will be further discussed.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"454-459"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osimertinib, metastatic epidermal growth factor receptor T790M mutation, and non-small cell lung cancer. 奥西替尼,转移性表皮生长因子受体T790M突变,非小细胞肺癌。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_373_22
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
{"title":"Osimertinib, metastatic epidermal growth factor receptor T790M mutation, and non-small cell lung cancer.","authors":"Rujittika Mungmunpuntipantip, Viroj Wiwanitkit","doi":"10.4103/ijc.ijc_373_22","DOIUrl":"https://doi.org/10.4103/ijc.ijc_373_22","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"464"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
News in Oncology. 肿瘤学新闻。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_8_25
Prakash Umbarkar, Prahlad H Yathiraj, Ritika H Hinduja
{"title":"News in Oncology.","authors":"Prakash Umbarkar, Prahlad H Yathiraj, Ritika H Hinduja","doi":"10.4103/ijc.ijc_8_25","DOIUrl":"https://doi.org/10.4103/ijc.ijc_8_25","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"467-470"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular endothelial growth factor: A potential prognosticator in Ewing sarcoma. 血管内皮生长因子:尤因肉瘤的潜在预后因子。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_632_23
Goutam Santosh Panda, Arun Chandrasekharan, Bharat Rekhi, Prabhat Bhargava, Siddhartha Laskar, Smruti Mokal, Nehal Khanna, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad D Banavali, Sudeep Gupta, Jyoti Bajpai

Background: Vascular endothelial growth factor (VEGF) is an angiogenic marker and is implicated in the carcinogenesis and prognostication of cancers. However, its prognostic potential in Ewing sarcoma (ES) merits exploration.

Methods: Histopathologically confirmed consecutive ES cases registered at our institute from 2014 to 2018 were analyzed. Immunohistochemical staining for VEGF was performed on tumor tissues, and they were further classified based on VEGF intensity.

Results: There were 105 patients (53 non-metastatic and 52 metastatic). VEGF immunostaining in non-metastatic and metastatic cohorts was negative in 20 (37.7%) and 21 (40.4%), mildly positive in 13 (24.5%) and 9 (17.3%) cases, moderately positive in 14 (26.4%) and 16 (30.8%), and was intensely positive in 6 (11.3%) and 7 (13.5%) patients, respectively. VEGF immunoexpression of up to 25% was seen in 14 (13.3%) and 10 (9.5%) patients within the non-metastatic and metastatic cohorts, respectively. For the non-metastatic cohort, the median EFS (months) was 78.6 (95% CI: 61.34-NA), whereas the median OS was not reached. The median EFS and OS (months) were 10.8 (95% CI: 6.41-17.1) and 13.5 (95% CI: 8.08-21.2), respectively, for the metastatic cohort. Metastatic ES patients having either VEGF immunostaining in >25% of tumor cells or moderate/strong immunostaining were found to have inferior OS (P = 0.008, HR = 10.565). In addition, metastatic patients who were treatment naïve had inferior OS, whereas patients who underwent definitive surgery and completed treatment had superior OS (P = 0.003, P = 0.015, and P = 0.009, respectively).

Conclusion: VEGF was found to be an independent prognostic marker in metastatic ESs. This may translate to therapeutic relevance but needs validation in the subsequent, larger prospective studies.

背景:血管内皮生长因子(VEGF)是一种血管生成标志物,与癌症的发生和预后有关。然而,它在尤文氏肉瘤(ES)中的预后潜力值得探索。方法:对我院2014 - 2018年连续登记的经组织病理学证实的ES病例进行分析。对肿瘤组织进行VEGF免疫组化染色,并根据VEGF强度进一步分类。结果:105例患者(非转移性53例,转移性52例)。VEGF免疫染色在非转移和转移组中分别阴性20例(37.7%)和21例(40.4%),轻度阳性13例(24.5%)和9例(17.3%),中度阳性14例(26.4%)和16例(30.8%),强烈阳性6例(11.3%)和7例(13.5%)。在非转移性和转移性队列中,VEGF免疫表达高达25%的患者分别为14例(13.3%)和10例(9.5%)。对于非转移性队列,中位EFS(月)为78.6 (95% CI: 61.34 na),而中位OS未达到。转移队列的中位EFS和OS(月)分别为10.8 (95% CI: 6.41-17.1)和13.5 (95% CI: 8.08-21.2)。转移性ES患者的肿瘤细胞中有25%的VEGF免疫染色或中/强免疫染色,其OS较差(P = 0.008, HR = 10.565)。此外,接受naïve治疗的转移性患者的OS较差,而接受最终手术并完成治疗的患者的OS较好(P = 0.003, P = 0.015和P = 0.009)。结论:VEGF是转移性ESs的独立预后指标。这可能转化为治疗相关性,但需要在后续更大的前瞻性研究中进行验证。
{"title":"Vascular endothelial growth factor: A potential prognosticator in Ewing sarcoma.","authors":"Goutam Santosh Panda, Arun Chandrasekharan, Bharat Rekhi, Prabhat Bhargava, Siddhartha Laskar, Smruti Mokal, Nehal Khanna, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad D Banavali, Sudeep Gupta, Jyoti Bajpai","doi":"10.4103/ijc.ijc_632_23","DOIUrl":"https://doi.org/10.4103/ijc.ijc_632_23","url":null,"abstract":"<p><strong>Background: </strong>Vascular endothelial growth factor (VEGF) is an angiogenic marker and is implicated in the carcinogenesis and prognostication of cancers. However, its prognostic potential in Ewing sarcoma (ES) merits exploration.</p><p><strong>Methods: </strong>Histopathologically confirmed consecutive ES cases registered at our institute from 2014 to 2018 were analyzed. Immunohistochemical staining for VEGF was performed on tumor tissues, and they were further classified based on VEGF intensity.</p><p><strong>Results: </strong>There were 105 patients (53 non-metastatic and 52 metastatic). VEGF immunostaining in non-metastatic and metastatic cohorts was negative in 20 (37.7%) and 21 (40.4%), mildly positive in 13 (24.5%) and 9 (17.3%) cases, moderately positive in 14 (26.4%) and 16 (30.8%), and was intensely positive in 6 (11.3%) and 7 (13.5%) patients, respectively. VEGF immunoexpression of up to 25% was seen in 14 (13.3%) and 10 (9.5%) patients within the non-metastatic and metastatic cohorts, respectively. For the non-metastatic cohort, the median EFS (months) was 78.6 (95% CI: 61.34-NA), whereas the median OS was not reached. The median EFS and OS (months) were 10.8 (95% CI: 6.41-17.1) and 13.5 (95% CI: 8.08-21.2), respectively, for the metastatic cohort. Metastatic ES patients having either VEGF immunostaining in >25% of tumor cells or moderate/strong immunostaining were found to have inferior OS (P = 0.008, HR = 10.565). In addition, metastatic patients who were treatment naïve had inferior OS, whereas patients who underwent definitive surgery and completed treatment had superior OS (P = 0.003, P = 0.015, and P = 0.009, respectively).</p><p><strong>Conclusion: </strong>VEGF was found to be an independent prognostic marker in metastatic ESs. This may translate to therapeutic relevance but needs validation in the subsequent, larger prospective studies.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"345-354"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Rs 100 "R+Cu" (resveratrol and copper) anti-cancer magic tablet controversy: Results of online survey among oncologists. 100卢比的“R+Cu”(白藜芦醇和铜)抗癌神奇片争议:肿瘤学家在线调查结果。
IF 1.1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-07-01 Epub Date: 2025-11-21 DOI: 10.4103/ijc.ijc_170_24
Purvish M Parikh, Narayanan Prasad, Raja Thirumalairaj, Prasanta R Mohapatra, Viraj Lavingya, Hari Menon, Ajay Bapna, Prakash Chitalkar, Govind B Kanakasetty, Vineet G Gupta, Arun Chandrasekharan, Indu B Aggarwal, Amish Vora

Background: Recently, there has been a lot of interest and controversy regarding the media reporting the impending availability of a Rs 100 nutraceutical to prevent the resurgence of cancer. The institution involved rapidly issued a statement to clarify the facts. We also decided to see the short-term effect of this episode on the practicing oncologist. Here we present the results of this survey.

Methods: A 13-question multiple-choice (MCQ) survey was created using Google Forms and circulated among oncologists via WhatsApp. Responses were collected over three days, and duplicate entries were deleted. Answers from oncologists who were not aware of the controversy were also excluded. In addition, opinions were documented regarding a social media video aimed at reducing misconceptions among the general public, and the views of oncologists who had seen the video were specifically analyzed.

Results: A total of 237 out of 240 responders were aware of the controversy and were analyzed. Majority (210/237; 88.6%) of the responders were of the opinion that the initial press release by Tata Memorial Center (TMC) was premature and not necessary resulted in misinterpretation by the media as well as the laypersons. The majority of the oncologists (177/237; 74.7%) also felt that the clarification" statement from TMC was too little, too late. Among the oncologists who had seen the social media video (190/237; 80.2%), more than 90% were of the opinion that it was factually correct, appropriate, and allowed the laypersons to understand the message correctly helping with patient counselling, and that it was not offensive to TMC.

Conclusion: Healthcare professionals and institutions that are centers of excellence have to be careful when announcing the results of a new potential breakthrough. The press and digital media have a tendency to exaggerate to convert this into breaking news. A rapid response by the institutions will help ensure that the misconception is correctly addressed by facts and references. The use of social media to reach out to laypeople is an effective additional tool to convey the correct message nationwide.

背景:最近,媒体报道了一种价值100卢比的营养保健品即将上市,以防止癌症复发,这引起了很多兴趣和争议。有关机构迅速发表声明澄清事实。我们还决定看看这个插曲对执业肿瘤学家的短期影响。在这里,我们展示了这次调查的结果。方法:采用谷歌表格进行13道选择题(MCQ)调查,并通过WhatsApp在肿瘤学家中进行分发。在三天内收集回复,并删除重复条目。不知道争议的肿瘤学家的回答也被排除在外。此外,还记录了一段旨在减少公众误解的社交媒体视频的意见,并对看过该视频的肿瘤学家的观点进行了具体分析。结果:240名应答者中有237名知晓争议并进行了分析。大多数(210/237;88.6%)的回应者认为塔塔纪念中心(TMC)最初的新闻发布是不成熟的,没有必要导致媒体和外行的误解。大多数肿瘤学家(177/237,74.7%)也认为TMC的澄清声明太少、太迟。在看过社交媒体视频的肿瘤科医生中(190/237;80.2%),超过90%的人认为这是事实正确,适当的,并且允许外行正确理解信息,有助于患者咨询,并且对TMC没有冒犯。结论:作为卓越中心的医疗保健专业人员和机构在宣布新的潜在突破的结果时必须谨慎。新闻界和数字媒体倾向于夸大事实,将其转化为突发新闻。各机构的迅速反应将有助于确保通过事实和参考资料正确解决误解。利用社交媒体来接触外行是在全国范围内传达正确信息的有效工具。
{"title":"The Rs 100 \"R+Cu\" (resveratrol and copper) anti-cancer magic tablet controversy: Results of online survey among oncologists.","authors":"Purvish M Parikh, Narayanan Prasad, Raja Thirumalairaj, Prasanta R Mohapatra, Viraj Lavingya, Hari Menon, Ajay Bapna, Prakash Chitalkar, Govind B Kanakasetty, Vineet G Gupta, Arun Chandrasekharan, Indu B Aggarwal, Amish Vora","doi":"10.4103/ijc.ijc_170_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_170_24","url":null,"abstract":"<p><strong>Background: </strong>Recently, there has been a lot of interest and controversy regarding the media reporting the impending availability of a Rs 100 nutraceutical to prevent the resurgence of cancer. The institution involved rapidly issued a statement to clarify the facts. We also decided to see the short-term effect of this episode on the practicing oncologist. Here we present the results of this survey.</p><p><strong>Methods: </strong>A 13-question multiple-choice (MCQ) survey was created using Google Forms and circulated among oncologists via WhatsApp. Responses were collected over three days, and duplicate entries were deleted. Answers from oncologists who were not aware of the controversy were also excluded. In addition, opinions were documented regarding a social media video aimed at reducing misconceptions among the general public, and the views of oncologists who had seen the video were specifically analyzed.</p><p><strong>Results: </strong>A total of 237 out of 240 responders were aware of the controversy and were analyzed. Majority (210/237; 88.6%) of the responders were of the opinion that the initial press release by Tata Memorial Center (TMC) was premature and not necessary resulted in misinterpretation by the media as well as the laypersons. The majority of the oncologists (177/237; 74.7%) also felt that the clarification\" statement from TMC was too little, too late. Among the oncologists who had seen the social media video (190/237; 80.2%), more than 90% were of the opinion that it was factually correct, appropriate, and allowed the laypersons to understand the message correctly helping with patient counselling, and that it was not offensive to TMC.</p><p><strong>Conclusion: </strong>Healthcare professionals and institutions that are centers of excellence have to be careful when announcing the results of a new potential breakthrough. The press and digital media have a tendency to exaggerate to convert this into breaking news. A rapid response by the institutions will help ensure that the misconception is correctly addressed by facts and references. The use of social media to reach out to laypeople is an effective additional tool to convey the correct message nationwide.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"365-371"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian journal of cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1